Gregory Divis was named President and Chief Executive Officer of InMed Pharmaceuticals Inc. As of November 14, 2026, InMed Pharmaceuticals Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 10, 2026, naming 2 appointments (Form 8-K, November 10, 2026).
InMed Pharmaceuticals Inc. named a new President and Chief Executive Officer on Nov 10. 29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like InMed Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
InMed Pharmaceuticals Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-10. It names 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as InMed Pharmaceuticals Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-03-06 (layoff filings and notices).
Also on the record for InMed Pharmaceuticals Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by Commodore Capital LP | 5.6% of the class | 5%+ stakes | Source |
| November 13, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 5.64% of the class | 5%+ stakes | Source |
| November 12, 2026 | Stake report, Schedule 13D, by Fairmount Funds Management LLC | 19.99% of the class | 5%+ stakes | Source |
| November 6, 2026 | Acquired Mentari | $490M | Acquisition | Source |
| October 7, 2026 | Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC | 17.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Ikarian Capital, LLC | 4.2% of the class | 5%+ stakes | Source |
| June 10, 2026 | Stake report, Schedule 13D, by Vivo Opportunity Fund Holdings, L.P. | 21.7% of the class | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 24.1% of the class | 5%+ stakes | Source |
| May 27, 2026 | Stake report, Schedule 13G, by Squadron Master Fund LP | 9.8% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13G, by SABBY MANAGEMENT, LLC | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs InMed Pharmaceuticals Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on InMed Pharmaceuticals Inc. and the records around it.
InMed Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Acquisition Nov 2026
- Layoff notices Mar 2026
- Who owns it
Companies that share a holder
- Fairmount Funds Management LLC also filed stake reports on 14 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
Watch InMed Pharmaceuticals Inc.
Get an email when InMed Pharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on InMed Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on InMed Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InMed Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-10 | In | President and Chief Executive Officer | 8-K, 2026-11-10 | ||
| 2026-11-10 | In | 8-K, 2026-11-10 |
Who leads InMed Pharmaceuticals Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President and Chief Executive Officer: Gregory Divis, appointed (filed 2026-11-10).
New leaders reset buying decisions — get the Full Report on InMed Pharmaceuticals Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President and Chief Executive Officer at InMed Pharmaceuticals Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at InMed Pharmaceuticals Inc.Every change, in the filing's words
Appointed: Gregory Divis, President and Chief Executive Officer
On November 6, 2026, the Company's board of directors appointed Gregory Divis as the Company's President and Chief Executive Officer, Brett Hagen as the Company's Senior Vice President, Finance and Chief Accounting Officer, and Jerad Seurer as the Company's General Counsel and Corporate Secretary, each to serve at the discretion of the Board.
Appointed: Brett Hagen
Mr. Hagen will serve as the Company's principal financial officer and principal accounting officer.
- Departure of Directors and Certain Officers On November 6, 2026, Eric A. Adams, John Bathery, Andrew Hull, Neil Klompas and Nicole Lemerond resigned from the Company's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.
- In addition, on November 6, 2026, Eric A. Adams, InMed's President and Chief Executive Officer, Neeta Jagpal, InMed's Chief Financial Officer and Corporate Secretary, Michael Woudenberg, InMed's Chief Operating Officer, and Eric Hsu, InMed's Senior Vice President, Preclinical Research & Development, each resigned as an executive officer of the Company at the Closing.
- The departures of Mr. Adams, Ms. Jagpal, Mr. Woudenberg and Dr. Hsu were not the result of any disagreement with InMed relating to InMed's operations, policies or practices.
- Stock Incentive Plan On September 29, 2026, InMed's board of directors approved the Mentari Therapeutics, Inc. 2026 Stock Incentive Plan (the "2026 Stock Plan"), subject to shareholder approval and the consummation of the Merger.
- On November 4, 2026, InMed's shareholders approved the 2026 Stock Plan at the InMed Shareholders Meeting.
Tools for this story
Each opens in a new tab, filled in for InMed Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
